Selective endothelinA receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease

@inproceedings{Girgis2007SelectiveER,
  title={Selective endothelinA receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease},
  author={Reda E. Girgis and Adaani E. Frost and Nicholas S Hill and Evelyn M. Horn and David Langleben and Vallerie and V McLaughlin and Ronald J. Oudiz and Ivan M. Robbins and James R. Seibold and Shelley Shapiro and Victor F. Tapson and Robyn J. Barst},
  year={2007}
}
Introduction: Endothelin receptor antagonism has become an important component in the treatment of pulmonary arterial hypertension (PAH) associated with connective tissue disease (CTD). The purpose of this study was to analyse the safety and effectiveness of sitaxsentan, a selective antagonist of the ETA receptor, in a cohort of patients with PAH and CTD. Short-term clinical and haemodynamic effects and longer-term followup data are presented. Methods: A post hoc subgroup analysis was performed… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 31 references

Chronic treatment of pulmonary arterial hypertension with sitaxsentan and bosentan

  • R Benza, A Frost, R Girgis, D Langleben, EC Lawrence, R. Naeije
  • Am J Respir Crit Care Med 2006;3:A729
  • 2006

Similar Papers

Loading similar papers…